Compare iShares International Treasury Bond ETF (IGOV) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares International Treasury Bond ETF trades at $39.75 (market cap $1.31B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 58.3× iShares International Treasury Bond ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares International Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| IGOV | REGN | |
|---|---|---|
Market Cap | $1.31B | $76.40B |
Volume | 493,216 | 626,381 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $852.03 |
52-Week Low | $39.65 | $557.73 |
Typical Hold Time | 92 Days | 107 Days |
Enterprise Value | — | $71.12B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV is trading at $39.70, down 0.48% on the day, with technical indicators showing a bearish trend as moving averages signal selling pressure. The stock lacks available fundamental data for key valuation and profitability metrics, creating uncertainty around its financial health. Recent market news highlights rising global bond yields, which could impact interest-rate sensitive sectors.
The outlook remains cautious due to the bearish technical setup and absence of fundamental clarity. Investment opportunities depend on forthcoming financial disclosures, while risks include market volatility from rising yields and the stock's technical weakness. Investors require updated earnings reports to assess true valuation.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
